

Paolo Marchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/81784/publications.pdf>

Version: 2024-02-01

367
papers

11,054
citations

47006

47
h-index

60623

81
g-index

381
all docs

381
docs citations

381
times ranked

15992
citing authors

#	ARTICLE	IF	CITATIONS
1	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	10.7	486
2	Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1361-1375.	3.6	358
3	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315
4	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
5	Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. <i>Oncotarget</i> , 2017, 8, 79884-79896.	1.8	239
6	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
7	Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. <i>Human Mutation</i> , 2001, 18, 163-164.	2.5	215
8	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
9	Use of strong opioids in advanced cancer pain: a randomized trial. <i>Journal of Pain and Symptom Management</i> , 2004, 27, 409-416.	1.2	160
10	Clinical experience with ipilimumab 3Âµg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	4.4	149
11	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	2.8	149
12	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
13	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	3.7	131
14	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	2.2	127
15	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	2.6	118
16	Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. <i>Journal of Translational Medicine</i> , 2020, 18, 49.	4.4	114
17	Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-Î± Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. <i>Cancer Research</i> , 2006, 66, 4943-4951.	0.9	108
18	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103

#	ARTICLE	IF	CITATIONS
19	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <i>European Journal of Endocrinology</i> , 2013, 169, R153-R164.	3.7	102
20	Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1092-1098.	0.8	98
21	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020, 130, 155-167.	2.8	98
22	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	8.6	97
23	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018, 16, 219.	4.4	96
24	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	1.3	90
25	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
26	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	7.7	83
27	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134.	2.8	83
28	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 13-33.	2.3	81
29	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
30	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
31	Italian Nivolumab Expanded Access Program in Non-small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77
32	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	1.8	76
33	Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8730.	4.1	75
34	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552.	4.8	74
35	Weekly administration of paclitaxel: theoretical and clinical basis. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 44, 3-13.	4.4	70
36	Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 27-42.	4.4	68

#	ARTICLE	IF	CITATIONS
37	Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. <i>European Journal of Pharmacology</i> , 2019, 862, 172621.	3.5	65
38	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	2.4	64
39	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
40	Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166042.	3.8	61
41	Early onset pancreatic cancer: Risk factors, presentation and outcome. <i>Pancreatology</i> , 2015, 15, 151-155.	1.1	60
42	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
43	A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-7.	1.2	59
44	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1478-1485.	1.6	59
45	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. <i>European Journal of Human Genetics</i> , 2004, 12, 899-906.	2.8	55
46	Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840.	4.6	55
47	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	3.8	54
48	Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study. <i>Journal of Cancer</i> , 2014, 5, 320-327.	2.5	53
49	Italian Oncological Pain Survey (IOPS). <i>Clinical Journal of Pain</i> , 2015, 31, 214-221.	1.9	53
50	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	1.8	53
51	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99.	4.4	52
52	Dermscopic patterns of cutaneous melanoma metastases. <i>Melanoma Research</i> , 2004, 14, 367-373.	1.2	51
53	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	4.4	51
54	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50

#	ARTICLE	IF	CITATIONS
55	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. BioMed Research International, 2017, 2017, 1-7.	1.9	49
56	Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. Oncotarget, 2018, 9, 30268-30278.	1.8	49
57	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget, 2017, 8, 8890-8899.	1.8	48
58	TK Inhibitor Pazopanib Primes DCs by Downregulation of the β -Catenin Pathway. Cancer Immunology Research, 2018, 6, 711-722.	3.4	47
59	Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 705096.	4.8	47
60	The Exponential Phase of the Covid-19 Pandemic in Central Italy: An Integrated Care Pathway. International Journal of Environmental Research and Public Health, 2020, 17, 3792.	2.6	46
61	Brain Metastases: Surgical Treatment and Overall Survival. World Neurosurgery, 2017, 97, 169-177.	1.3	45
62	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
63	Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. Cancers, 2018, 10, 175.	3.7	44
64	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer, 2019, 137, 38-42.	2.0	44
65	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 975-983.	2.4	43
66	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Translational Lung Cancer Research, 2020, 9, 1533-1542.	2.8	43
67	Cytokines, Fatigue, and Cutaneous Erythema in Early Stage Breast Cancer Patients Receiving Adjuvant Radiation Therapy. BioMed Research International, 2014, 2014, 1-7.	1.9	42
68	Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic) Tj ETQq0 0 0,rgBT /Overlock 10 T	2.2	42
69	Nutritional support for cancer patients: still a neglected right?. Supportive Care in Cancer, 2017, 25, 3001-3004.	2.2	42
70	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2019, 37, 9013-9013.	1.6	42
71	Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget, 2018, 9, 25714-25722.	1.8	42
72	"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (Flr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer, 2010, 10, 567.	2.6	41

#	ARTICLE	IF	CITATIONS
73	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1607.	4.1	40
74	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. <i>The RETROHER study. Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	2.5	39
75	Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 279-284.	0.9	39
76	Awareness of cancer, satisfaction with care, emotional distress, and adjustment to illness: an Italian multicenter study. <i>Psycho-Oncology</i> , 2015, 24, 1088-1096.	2.3	38
77	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38
78	Dignity and Psychosocial-Related Variables in Advanced and Nonadvanced Cancer Patients by Using the Patient Dignity Inventory-Italian Version. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 279-287.	1.2	38
79	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	4.4	38
80	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	4.4	36
81	The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patients's™ Oncological Pathway. <i>PLoS ONE</i> , 2016, 11, e0157300.	2.5	36
82	High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. <i>Digestive and Liver Disease</i> , 2016, 48, 1503-1505.	0.9	35
83	CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332.	3.7	35
84	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4737-4745.	7.0	35
85	Overcoming Cultural Barriers to Giving Bad News: Feasibility of Training to Promote Truth-Telling to Cancer Patients. <i>Journal of Cancer Education</i> , 2009, 24, 180-185.	1.3	34
86	Treatment-related side effects and quality of life in cancer patients. <i>Supportive Care in Cancer</i> , 2012, 20, 2553-2557.	2.2	34
87	Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. <i>International Journal of Oncology</i> , 2016, 48, 1581-1589.	3.3	34
88	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	7.7	34
89	Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?. <i>Gut and Liver</i> , 2014, 8, 102-108.	2.9	34
90	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33

#	ARTICLE	IF	CITATIONS
91	High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adolescents and young adults. <i>Lung Cancer</i> , 2016, 97, 95-98.	2.0	33
92	Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 17-24.	1.2	33
93	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221.	4.4	33
94	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	4.1	33
95	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	1.1	33
96	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	2.0	33
97	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	1.8	33
98	Intradermal lymphoscintigraphy at rest and after exercise: a new technique for the functional assessment of the lymphatic system in patients with lymphoedema. <i>Nuclear Medicine Communications</i> , 2010, 31, 547-551.	1.1	32
99	Premetastatic niche: ready for new therapeutic interventions?. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S119-S129.	3.4	32
100	Being positive despite illness: The contribution of positivity to the quality of life of cancer patients. <i>Psychology and Health</i> , 2016, 31, 524-534.	2.2	32
101	The factor structure and use of the Demoralization Scale (DS&T) in Italian cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1965-1971.	2.3	32
102	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	8.6	32
103	Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 547.	7.1	32
104	A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 482-488.	2.0	31
105	The Supportive Care Task Force at the University of L'Aquila: 2-years experience. <i>Supportive Care in Cancer</i> , 2005, 13, 351-355.	2.2	30
106	Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link?. <i>International Journal of Cardiology</i> , 2013, 167, 2421-2429.	1.7	30
107	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	3.4	30
108	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528.	4.1	30

#	ARTICLE	IF	CITATIONS
109	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	4.8	30
110	Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab. <i>Clinical Colorectal Cancer</i> , 2012, 11, 119-126.	2.3	29
111	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	1.1	29
112	Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. <i>Medical Oncology</i> , 2018, 35, 111.	2.5	29
113	Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. <i>Journal of Clinical Medicine</i> , 2019, 8, 910.	2.4	28
114	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	2.5	28
115	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2065-2077.	1.1	28
116	Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy. <i>Archives of Dermatology</i> , 2005, 141, 1173-4.	1.4	27
117	Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 289-296.	2.5	27
118	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	4.8	27
119	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	4.4	27
120	Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). <i>Tumori</i> , 2017, 103, 9-14.	1.1	26
121	Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3896.	2.5	26
122	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	4.4	26
123	Predictors of existential and religious well-being among cancer patients. <i>Supportive Care in Cancer</i> , 2011, 19, 1931-1937.	2.2	25
124	Use of interim [¹⁸ F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 263-269.	1.3	25
125	Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. <i>Medical Oncology</i> , 2015, 32, 54.	2.5	25
126	Current achievements and future perspectives of metronomic chemotherapy. <i>Investigational New Drugs</i> , 2017, 35, 359-374.	2.6	25

#	ARTICLE	IF	CITATIONS
127	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	2.8	25
128	CT based radiomic approach on first line pembrolizumab in lung cancer. <i>Scientific Reports</i> , 2021, 11, 6633.	3.3	25
129	Changes of Topoisomerase III \pm Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. <i>Clinical Cancer Research</i> , 2006, 12, 1501-1506.	7.0	24
130	Short-term Radiotherapy followed by Adjuvant Chemotherapy in Poor-Prognosis Patients with Glioblastoma. <i>Tumori</i> , 2010, 96, 60-64.	1.1	24
131	Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 396-404.	1.3	24
132	Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 826-831.	3.4	24
133	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 590263.	3.6	24
134	The role of opioids in cancer response to immunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 119.	4.4	24
135	Predictors of mood disorders in cancer patients's caregivers. <i>Supportive Care in Cancer</i> , 2013, 21, 643-647.	2.2	23
136	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 125.	1.9	23
137	Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial. <i>Clinical Colorectal Cancer</i> , 2016, 15, 377-380.	2.3	23
138	SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. <i>Medical Oncology</i> , 2017, 34, 75.	2.5	23
139	Study of histopathologic parameters to define the prognosis of stage II colon cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 905-913.	2.2	23
140	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	3.7	23
141	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208.	2.5	23
142	Changes of microbiome profile during nivolumab treatment in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15020-e15020.	1.6	23
143	Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 71-79.	2.5	22
144	High Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 121-132.	0.7	22

#	ARTICLE	IF	CITATIONS
145	Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-12.	1.4	22
146	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	2.8	22
147	Steroid receptor enhancement by natural interferon- β in advanced breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 329-333.	2.8	21
148	Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 83-91.	2.5	21
149	Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. <i>Oncotarget</i> , 2016, 7, 20612-20620.	1.8	21
150	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016, 12, 2071-2075.	2.4	21
151	Ion Channel Expression in Human Melanoma Samples: In Silico Identification and Experimental Validation of Molecular Targets. <i>Cancers</i> , 2019, 11, 446.	3.7	21
152	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	4.1	21
153	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2620.	3.7	21
154	Glucocorticoid Receptors Predict Response to Combination Chemotherapy in Patients with Acute Lymphoblastic Leukemia. <i>Oncology</i> , 1987, 44, 13-16.	1.9	20
155	Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986692.	2.0	20
156	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019, 17, 376.	4.4	20
157	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
158	Information Needs of Patients With Melanoma. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, 625-632.	0.6	19
159	Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). <i>Advances in Therapy</i> , 2017, 34, 120-135.	2.9	19
160	CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 569-576.	2.8	19
161	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter SLAVE- Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
162	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	4.1	19

#	ARTICLE	IF	CITATIONS
163	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	3.2	19
164	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e457-e470.	2.3	18
165	Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. <i>Anticancer Research</i> , 2018, 38, 6029-6039.	1.1	18
166	Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?. <i>Clinical Endocrinology</i> , 2020, 92, 258-265.	2.4	18
167	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639.	2.8	18
168	Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study. <i>Cancers</i> , 2021, 13, 6355.	3.7	18
169	Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e55-e59.	2.3	17
170	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	4.1	17
171	Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. <i>Clinical Drug Investigation</i> , 2019, 39, 825-834.	2.2	17
172	Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPSAEMS study. <i>European Journal of Pain</i> , 2019, 23, 719-726.	2.8	17
173	Glucocorticoid receptor studies in human leukemia. <i>The Journal of Steroid Biochemistry</i> , 1981, 15, 261-268.	1.1	16
174	Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1069-1075.	0.8	16
175	Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. <i>European Journal of Human Genetics</i> , 2006, 14, 49-54.	2.8	16
176	Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 489-490.	2.3	16
177	Differential Denaturation of Serum Proteome Reveals a Significant Amount of Hidden Information in Complex Mixtures of Proteins. <i>PLoS ONE</i> , 2013, 8, e57104.	2.5	16
178	A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 106-111.	1.4	16
179	Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 450-459.	3.2	16
180	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	3.3	16

#	ARTICLE	IF	CITATIONS
181	A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	4.1	16
182	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	4.4	16
183	Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience. <i>Radiation Oncology</i> , 2019, 14, 205.	2.7	16
184	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	2.5	16
185	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	2.4	16
186	High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 86-91.	2.8	15
187	New mutations and protein variants of NBS1 are identified in cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 198-204.	2.8	15
188	Topical Morphine in the Treatment of Painful Ulcers. <i>Journal of Pain and Symptom Management</i> , 2005, 30, 304-305.	1.2	15
189	Clinical Classification of <i>BRCA1</i> DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain. <i>Journal of Clinical Oncology</i> , 2008, 26, 4212-4214.	1.6	15
190	Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. <i>Oncologist</i> , 2015, 20, 1111-1118.	3.7	15
191	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	4.4	15
192	Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma. <i>Medicine (United States)</i> , 2010, 89, 1015-1016.	1.0	15
193	Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. <i>Drug Safety - Case Reports</i> , 2018, 5, 12.	0.9	15
194	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 147.	3.7	15
195	No Evidence of SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a Retrospective Surveillance. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8461.	2.6	15
196	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15
197	Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. <i>Oncotarget</i> , 2017, 8, 113472-113493.	1.8	15
198	Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. <i>Anticancer Research</i> , 2014, 34, 6265-9.	1.1	15

#	ARTICLE	IF	CITATIONS
199	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009, 18, 2-7.	2.2	14
200	The role of stereotactic body radiation therapy in oligometastatic colorectal cancer. <i>Medicine (United States)</i> , 2017, 96, e9023.	1.0	14
201	Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for <sc>NSCLC</sc>. <i>Cancer Reports</i> , 2021, 4, e1368.	1.4	14
202	Molecular tests and target therapies in oncology: recommendations from the Italian workshop. <i>Future Oncology</i> , 2021, 17, 3529-3539.	2.4	14
203	Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. <i>Anticancer Research</i> , 2014, 34, 5241-50.	1.1	14
204	Genomic and epigenomic alterations in prostate cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 128.	3.5	13
205	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	7.7	13
206	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	4.4	13
207	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13
208	The 5-Ws of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041.	4.4	13
209	Patient perception of disease control and psychological distress. <i>Cancer Management and Research</i> , 2012, 4, 335.	1.9	12
210	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	4.1	12
211	Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons. <i>Tumori</i> , 2016, 102, 472-480.	1.1	12
212	Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. <i>Pharmacogenomics</i> , 2017, 18, 821-830.	1.3	12
213	Patient database analysis of fulvestrant 500mg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017, 32, 247-255.	2.2	12
214	Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 157-164.	1.9	12
215	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	3.4	12
216	Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. <i>Supportive Care in Cancer</i> , 2018, 26, 4021-4029.	2.2	12

#	ARTICLE	IF	CITATIONS
217	Impact of tumor site on the prognosis of small bowel adenocarcinoma. <i>Tumori</i> , 2019, 105, 524-528.	1.1	12
218	Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Supportive Care in Cancer</i> , 2019, 27, 4083-4090.	2.2	12
219	Primary squamous cell carcinoma of major salivary gland: Sapienza Head and Neck Unit's clinical recommendations. <i>Rare Tumors</i> , 2020, 12, 203636132097352.	0.6	12
220	Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study. <i>Cancers</i> , 2021, 13, 4018.	3.7	12
221	Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. <i>Supportive Care in Cancer</i> , 2006, 14, 389-391.	2.2	11
222	Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1183-1198.	2.4	11
223	The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 1044-1049.	1.4	11
224	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176.	4.4	11
225	H-Ras gene takes part to the host immune response to COVID-19. <i>Cell Death Discovery</i> , 2021, 7, 158.	4.7	11
226	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	1.8	11
227	Interventions to Reduce Neurological Symptoms in Patients with GBM Receiving Radiotherapy: From Theory to Clinical Practice. <i>Anticancer Research</i> , 2018, 38, 2423-2427.	1.1	11
228	Prediction of clinical response to glucocorticoids in children with acute lymphoblastic leukemia. <i>European Paediatric Haematology and Oncology</i> , 1984, 1, 33-36.	0.3	10
229	Complete Regression of a Non-small Cell Lung Cancer Choroidal Metastasis with Intravitreal Bevacizumab. <i>Journal of Thoracic Oncology</i> , 2012, 7, 468-469.	1.1	10
230	Gastric Metastases From Testicular Cancer: Case Report and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 22-24.	1.3	10
231	Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?. <i>PLoS ONE</i> , 2016, 11, e0163105.	2.5	10
232	5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. <i>Anti-Cancer Drugs</i> , 2017, 28, 322-326.	1.4	10
233	A nomogram to predict 5-fluorouracil toxicity. <i>Anti-Cancer Drugs</i> , 2017, 28, 551-556.	1.4	10
234	Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, e17-e20.	3.4	10

#	ARTICLE	IF	CITATIONS
235	IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. <i>EBioMedicine</i> , 2020, 62, 103098.	6.1	10
236	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648.	3.7	10
237	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020, 4, 1339-1349.	3.0	10
238	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	4.4	10
239	New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP. <i>Discover Oncology</i> , 2021, 12, 6.	2.1	10
240	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080.	3.7	10
241	Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy. <i>World Journal of Oncology</i> , 2015, 6, 394-397.	1.5	10
242	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1027-1037.	7.0	10
243	Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 605-609.	2.5	9
244	A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. <i>Case Reports in Medicine</i> , 2014, 2014, 1-6.	0.7	9
245	Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 712-719.	2.8	9
246	The use of fentanyl in pain management in head and neck cancer patients: a narrative review. <i>British Journal of Pain</i> , 2018, 12, 155-162.	1.5	9
247	Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation. <i>Medicine (United States)</i> , 2018, 97, e10904.	1.0	9
248	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373.	2.5	9
249	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1439-1444.	0.9	9
250	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	4.6	9
251	Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT26.	1.5	9
252	Drugâ€™Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PINÂ® System Comprehensive Approach. <i>Pharmaceuticals</i> , 2021, 14, 67.	3.8	9

#	ARTICLE	IF	CITATIONS
253	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. <i>Tumori</i> , 2022, 108, 250-257.	1.1	9
254	Radiotherapy with or without Androgen Deprivation in the Treatment of Localized Adenocarcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 1-5.	1.3	9
255	H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 926-929.	1.6	9
256	CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy. <i>Eurasian Journal of Medicine</i> , 2016, 48, 10-14.	0.6	9
257	Assessment and treatment of symptoms among Italian medical oncologists. <i>Supportive Care in Cancer</i> , 2005, 13, 865-869.	2.2	8
258	Tackling pancreatic cancer with metronomic chemotherapy. <i>Cancer Letters</i> , 2017, 394, 88-95.	7.2	8
259	Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know. <i>Tumori</i> , 2019, 105, NP48-NP51.	1.1	8
260	5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1836-1842.	0.9	8
261	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781.	3.7	8
262	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	3.3	8
263	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , 2020, 25, e928-e935.	3.7	8
264	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <i>OncoTargets and Therapy</i> , 2013, 6, 1761.	2.0	7
265	Positive impact of elastography in breast cancer diagnosis: an institutional experience. <i>Journal of Ultrasound</i> , 2015, 18, 321-327.	1.3	7
266	Attitudes Among Patients With Advanced Cancer Toward Euthanasia and Living Wills. <i>Journal of Pain and Symptom Management</i> , 2016, 51, e3-e6.	1.2	7
267	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
268	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	2.2	7
269	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. <i>Supportive Care in Cancer</i> , 2021, 29, 7845-7854.	2.2	7
270	Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. <i>Anticancer Research</i> , 2017, 37, 2633-2639.	1.1	7

#	ARTICLE	IF	CITATIONS
271	Presence and steroid inducibility of glutamine synthetase in human leukemic cells. <i>The Journal of Steroid Biochemistry</i> , 1983, 19, 1665-1670.	1.1	6
272	Natural Interferon- β Treatment and Steroid Hormone Receptors in Primary Endometrial Cancer. <i>Gynecologic Oncology</i> , 1993, 50, 185-190.	1.4	6
273	Knowledge and attitudes of italian medical oncology residents toward the approach and treatment of pain. <i>Journal of Pain and Symptom Management</i> , 2003, 26, 590-592.	1.2	6
274	Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. <i>Supportive Care in Cancer</i> , 2004, 12, 208-209.	2.2	6
275	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. <i>BMC Cancer</i> , 2012, 12, 216.	2.6	6
276	A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2589-2602.	2.4	6
277	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2017, 28, 110-115.	1.4	6
278	Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. <i>Oncotarget</i> , 2017, 8, 14050-14057.	1.8	6
279	Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological ward. <i>Supportive Care in Cancer</i> , 2018, 26, 1961-1966.	2.2	6
280	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	2.6	6
281	Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.3	6
282	Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms. <i>Frontiers in Endocrinology</i> , 2019, 10, 757.	3.5	6
283	'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten et al: another point of view. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216867.	0.9	6
284	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	6
285	Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. <i>Journal of Personalized Medicine</i> , 2021, 11, 424.	2.5	6
286	Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695136.	2.8	6
287	Provision of Palliative Care and Pain Management Services for Oncology Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-17-S-27.	4.9	5
288	Widespread Renal Polycystosis Induced by Crizotinib. <i>Tumori</i> , 2015, 101, e128-e131.	1.1	5

#	ARTICLE	IF	CITATIONS
289	Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. <i>Journal of Thoracic Disease</i> , 2017, 9, E985-E989.	1.4	5
290	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	2.4	5
291	Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?. <i>Cancers</i> , 2021, 13, 4061.	3.7	5
292	FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. <i>World Journal of Oncology</i> , 2015, 6, 437-440.	1.5	5
293	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	17.0	5
294	Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	5
295	Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. <i>Current Signal Transduction Therapy</i> , 2012, 7, 265-288.	0.5	4
296	A rare case of palatin tonsillar metastasis from small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 709-711.	2.8	4
297	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	2.5	4
298	Evolving treatments for advanced gastric cancer: appraisal of the survival trend. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 717-729.	2.4	4
299	The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy. <i>Alcohol and Alcoholism</i> , 2019, 54, 47-50.	1.6	4
300	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
301	Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial. <i>Cancers</i> , 2020, 12, 3084.	3.7	4
302	Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , 2020, 10, 291.	2.5	4
303	The Challenge of ICLs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?. <i>Frontiers in Immunology</i> , 2021, 12, 704942.	4.8	4
304	Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1237-1245.	1.9	4
305	Pain evaluation and management: a survey of Italian radiotherapists. <i>Supportive Care in Cancer</i> , 2005, 13, 215-218.	2.2	3
306	Natural medicine: a "new frontier" in oncology?. <i>Annals of Oncology</i> , 2005, 16, 339-340.	1.2	3

#	ARTICLE	IF	CITATIONS
307	Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement. <i>Tumori</i> , 2016, 102, e25-e27.	1.1	3
308	Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law. <i>Pain Medicine</i> , 2017, 18, 1822-1824.	1.9	3
309	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	2.6	3
310	Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice. <i>Supportive Care in Cancer</i> , 2019, 27, 3531-3535.	2.2	3
311	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020, 29, e13174.	1.5	3
312	Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. <i>Pancreatology</i> , 2020, 20, 1149-1154.	1.1	3
313	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457.	3.7	3
314	Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 423-430.	1.4	3
315	Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. <i>Endocrine</i> , 2020, 68, 230-232.	2.3	3
316	A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1957-1961.	2.2	3
317	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 253-253.	1.6	3
318	PAX3d mRNA over 2.76 copies/ μ L in the bloodstream predicts cutaneous malignant melanoma relapse. <i>Oncotarget</i> , 2017, 8, 85479-85491.	1.8	3
319	Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy. <i>In Vivo</i> , 2021, 35, 3355-3360.	1.3	3
320	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	6.3	3
321	The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1353-1369.	1.9	3
322	Palliative Care in Advanced Cancer Patients: Waiting for Godot. <i>Oncologist</i> , 2012, 17, e8-9; author reply e12.	3.7	2
323	The Pan European Emesis Registry (PEER): a critical appraisal of the Italian experience. <i>Journal of Chemotherapy</i> , 2013, 25, 309-317.	1.5	2
324	Multidisciplinary approach to fetal adenocarcinoma of the lung: A case report. <i>Thoracic Cancer</i> , 2014, 5, 97-100.	1.9	2

#	ARTICLE	IF	CITATIONS
325	Supportive care services in hemato-oncology centers: a national survey. <i>Supportive Care in Cancer</i> , 2016, 24, 4407-4411.	2.2	2
326	Risk Management of Onco-Hematological Drugs: How and how Fast can we Improve?. <i>Tumori</i> , 2016, 102, S15-S29.	1.1	2
327	Complete Tumor Response with Afatinib 20Âmg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Clinical Drug Investigation</i> , 2017, 37, 581-585.	2.2	2
328	Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2019, 30, 201-204.	1.4	2
329	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. <i>Cancers</i> , 2020, 12, 849.	3.7	2
330	Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. <i>Cancer Management and Research</i> , 2021, Volume 13, 1747-1756.	1.9	2
331	A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2273.	2.4	2
332	An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case) Tj ETQq0 0 0 rgBT/Overlock, 10 Tf 50 4	2.2	2
333	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	2.8	2
334	Vitiligo-like leukodermaÂas an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	2
335	Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, placebo controlled, randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS10129-TPS10129.	1.6	2
336	A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 178.	3.7	2
337	Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3087-3087.	1.6	2
338	Inappropriate Doses of Chemotherapy in Italian Breast Cancer Patients Enrolled in Clinical Trials. <i>Tumori</i> , 2007, 93, 540-543.	1.1	1
339	Re. â€œAwareness and consideration of malnutrition among oncologists: Insights from an exploratory surveyâ€. <i>Nutrition</i> , 2017, 39-40, 96-97.	2.4	1
340	4th ESPT Conference: pharmacogenomics and personalized medicineÂâ€ research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019, 20, 1063-1069.	1.3	1
341	Response to: Comment on â€œImpact of tumor site on the prognosis of small bowel adenocarcinomaâ€. <i>Tumori</i> , 2019, 105, 532-532.	1.1	1
342	Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020, 18, 446.	4.4	1

#	ARTICLE	IF	CITATIONS
343	Phase 2 of coronavirus disease (COVID-19) and head and neck cancer: An action plan. <i>Oral Diseases</i> , 2022, 28, 970-972.	3.0	1
344	Risk of coronavirus disease 2019 in patients treated for cancer: An immune response-based hypothesis. <i>European Journal of Cancer</i> , 2020, 134, 6-8.	2.8	1
345	Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. <i>Journal of Translational Medicine</i> , 2021, 19, 303.	4.4	1
346	The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1055-1055.	1.6	1
347	Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line Flr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15041-e15041.	1.6	1
348	The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 797157.	2.8	1
349	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13.	1.1	1
350	Suppressive immune profile in combined positive score positive head and neck cancer patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18014-e18014.	1.6	1
351	Timed-Flat Infusion of 5-Fluorouracil Associated with Docetaxel as First-Line Treatment of Patients with Metastatic Breast Cancer. <i>Breast Journal</i> , 2008, 14, 116-117.	1.0	0
352	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058.	2.2	0
353	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
354	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15568-e15568.	1.6	0
355	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15588-e15588.	1.6	0
356	Commentary on "A Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapy" <i>Cancer Research and Treatment</i> , 2016, 48, 422-424.	3.0	0
357	Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15588-e15588.	1.6	0
358	Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 177-177.	1.6	0
359	Next-generation expression analysis (NanoString) to develop prognostic and predictive gene signatures for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 700-700.	1.6	0
360	Anatomic site of metastases can influence response to nivolumab in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15021-e15021.	1.6	0

#	ARTICLE	IF	CITATIONS
361	Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. Journal of Clinical Oncology, 2018, 36, e15158-e15158.	1.6	0
362	Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in <i>RAS</i> wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. Journal of Clinical Oncology, 2018, 36, e15517-e15517.	1.6	0
363	Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderlyâ€” Preliminary results of the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2018, 36, e13078-e13078.	1.6	0
364	The microbiota impact: bacteria shaping immunity, disease and response to therapy. Translational Cancer Research, 2018, 7, S616-S619.	1.0	0
365	Is it possible to teach pain therapy playing basketball?. Annals of Palliative Medicine, 2016, 5, 71-3.	1.2	0
366	Immunotherapy and chemo-immunotherapy for nonâ€”small cell lung cancer with novel actionable oncogenic driver alterations.. Journal of Clinical Oncology, 2022, 40, 9057-9057.	1.6	0
367	Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with antiâ€”PD-1.. Journal of Clinical Oncology, 2022, 40, 2553-2553.	1.6	0